Particle.news
Health ❯ Healthcare ❯ Cancer Treatment
Recovery Process Neoadjuvant Chemotherapy Patient Experience Recovery Drug Resistance Survivorship Chemoresistance Targeted Therapy Surgery Drug Mechanisms Antimetabolics Public Impact Targeted Drug Therapy DNA Damage Response Personal Experiences Patient Support Chemotherapy-Induced Peripheral Neuropathy Dose Adjustment mFOLFOX6 Regimen Targeted Therapies Drug Dosing Chemotherapy Resistance Side Effects Exercise Programs Fertility Risks FOLFOX Regimen Neoadjuvant Therapy Temozolomide Postoperative Complications Radiotherapy Patient Outcomes Kinase Inhibitors BrECADD Regimen Treatment Protocols Acute Myeloid Leukemia Patient Autonomy Daunorubicin Hair Loss Emotional Support Drug Development Non-Small Cell Lung Cancer Cisplatin/Carboplatin-Etoposide Clinical Research Liver Injury Hepatic Artery Infusion Pump Immunotherapy Leukemia Treatment Patient Experiences Diagnostic Tests Sacituzumab Tirumotecan Treatment Disruptions Metastatic Cancer District Day Care Chemotherapy Centre Proton Beam Therapy Personalized Medicine Princess of Wales Nausea Management Conventional Chemotherapy Mental Health
Presented at ESMO with a concurrent NEJM publication, the phase 3 data indicate a potential new first-line option for patients ineligible for immunotherapy pending mature survival results.
